FDA grants full ap­proval to Keytru­da in tu­mor-ag­nos­tic set­ting; Can­del paus­es tri­al en­roll­ment

In a first, Mer­ck has se­cured a full ap­proval for Keytru­da in a tu­mor ag­nos­tic set­ting — as a treat­ment for any un­re­sectable or metasta­t­ic sol­id tu­mors that are clas­si­fied as mi­crosatel­lite in­sta­bil­i­ty-high (MSI-H) or mis­match re­pair de­fi­cient (dMMR).

The FDA grant­ed Keytru­da ac­cel­er­at­ed ap­proval in this in­di­ca­tion in 2017, and GSK’s Jem­per­li fol­lowed suit in 2021. But now it’s con­vert­ed to a full ap­proval for Keytru­da. Be­fore pre­scrib­ing, doc­tors would have to make sure pa­tients car­ry this bio­mark­er, us­ing an FDA-ap­proved test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER